Prescription Automatic Screening Systems (PASS) are built on pharmaceutical knowledge bases and prescription review rules. Their primary applications include pre-prescription medication appropriateness screening, pharmacist-led prescription review and intervention during the prescribing process, post-prescription evaluation and medication quality management, pharmaceutical information services, clinical pharmacy, and patient medication services.
China's PASS market grew from RMB 490 million in 2021 to RMB 870 million in 2025 and is projected to reach RMB 4.24 billion by 2035. The market currently features one clear leader, while the remaining participants are relatively fragmented. Leading vendors derive their competitive advantages primarily from extensive pharmaceutical knowledge bases and accumulated review rules, established hospital customer networks, and strong project implementation and delivery capabilities.
Looking ahead, market expansion is expected to be driven by increasingly stringent prescription review and medication safety requirements, the development of integrated county-level healthcare networks, continued upgrades to hospital information systems, DRG/DIP payment reforms, electronic prescription circulation, and the growth of pharmaceutical care services. The adoption of artificial intelligence, expansion into both in-hospital and out-of-hospital medication scenarios, and demand for the upgrading, capacity expansion, and replacement of installed systems are expected to become key drivers of the industry's sustained growth.
